The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...

The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...

It is not clear what specifically the new facility will produce, though Amgen could be ramping up its manufacturing capacity ...

We recently published a list of 12 Best Affordable Stocks To Buy Right Now. In this article, we are going to take a look at ...

With that let’s take a look at the 12 best affordable stocks to buy right now.

Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...

The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.

The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

Health care stocks have underperformed in recent months on uncertainty surrounding the incoming Donald Trump administration, but they can often be a solid defensive play in an uncertain economy.